Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298752 · ClinicalTrials.gov registry record · Phase 3
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
NCT01298752: Clinical Trial Phase 3 study, sponsored by Bausch & Lomb Incorporated.
NCT01298752 is a Phase 3 study that was terminated before completion, run by Bausch & Lomb Incorporated. The registered enrollment target is 177 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01298752, a Phase 3 study, was terminated before completion, sponsored by Bausch & Lomb Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
Study Summary
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
Primary Outcome
Anterior chamber (AC) cells were assessed using a 0 to 4 grading scale by an ophthalmologist using slip lamp biomicroscopy. A slit lamp examination of the lids, conjunctiva, limbus, cornea, anterior chamber, vitreous, and lens was performed without pupil dilation. Accumulation of white blood cells in aqueous was assessed. The grades were defined as: 0 = No cells seen; 1 = 1 - 5 cells; 2 = 6 - 15 cells; 3 = 16 - 30 cells; 4 = \>30 cells. Complete resolution of AC cells was defined as Grade 0.
Interventions
- DRUG Vehicle
- DRUG Mapracorat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Why NCT01298752 stopped before completion
NCT01298752 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01298752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01298752 about?
NCT01298752 is a clinical study titled "Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery". The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
What is the current status of trial NCT01298752?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2011-02. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01298752?
The interventions under investigation include: Vehicle (DRUG), Mapracorat (DRUG).
Who is sponsoring clinical trial NCT01298752?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01298752's enrollment target sits among peer trials
177 1438th of 2000 higher than 563 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia